Long-term dietary treatment of hyperlipidaemia in patients treated with chronic haemodialysis.

bupivacaine, and neurotoxic reactions after the use of lignocaine for intravenous regional analgesia. Symptoms have ranged from headache and dizziness to loss of consciousness and convulsions.2 4 Reports of adverse reactions after intravenous regional analgesia with bupivacaine are few and the symptoms minimal.' Ware reported mild transient drowsiness after release of the cuff in only one patient out of a total of 2500 using 1-5 mg/kg of 0 2%, bupivacaine for intravenous regional analgesia.2 The low incidence of adverse effects is thought to be due to the high protein-binding property of bupivacaine. Normally over 90% is bound to plasma proteins and consequently very little "free" drug is available for systemic action. Measurements of peak plasma concentrations after intravenous regional analgesia with bupivacaine also confirm a wide safety margin. Peak concentrations occur at about three minutes after deflation of the cuff (840 ng/ml). That is about half the accepted minimum toxic concentration for this drug (1600 ng/ml).1 5